Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Pierre J Issa

Showing results (181-190 of 204) with videos related to

Pageof 21
Sort By:
Genome Biology|December 26, 2013
Architecture of epigenetic reprogramming following Twist1-mediated epithelial-mesenchymal transitionGabriel G Malouf, Joseph H Taube, Yue Lu, et al.
The Lancet. Oncology|August 23, 2015
Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 studyJean-Pierre J Issa, Gail Roboz, David Rizzieri, et al.
Scientific Reports|September 19, 2013
Epigenetic silencing of microRNA-203 is required for EMT and cancer stem cell propertiesJoseph H Taube, Gabriel G Malouf, Emily Lu, et al.
Cancer Research|November 6, 2009
Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinomaYasuhiro Goto, Keiko Shinjo, Yutaka Kondo, et al.
Clinical Epigenetics|May 14, 2020
Promoter methylation changes in ALOX12 and AIRE1: novel epigenetic markers for atherosclerosisJee Yeon Kim, Bong-Geun Choi, Jaroslav Jelinek, et al.
The Lancet. Haematology|May 8, 2019
Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trialGuillermo Garcia-Manero, Gail Roboz, Katherine Walsh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2002
Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylateHagop M Kantarjian, Susan O'Brien, Jorge E Cortes, et al.
Plos One|November 1, 2023
Postmortem toxicology findings from the Camden Opioid Research InitiativeDara M Kusic, Jessica Heil, Stefan Zajic, et al.
Cancer|December 7, 2017
Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemiaGail J Roboz, Hagop M Kantarjian, Karen W L Yee, et al.
Cancer Research|January 1, 2016
Targeting Calcium Signaling Induces Epigenetic Reactivation of Tumor Suppressor Genes in CancerNoël J-M Raynal, Justin T Lee, Youjun Wang, et al.
Pageof 21

Showing results (181-190 of 204) with videos related to

Sort By:
Pageof 21
Genome Biology|December 26, 2013
Architecture of epigenetic reprogramming following Twist1-mediated epithelial-mesenchymal transitionGabriel G Malouf, Joseph H Taube, Yue Lu, et al.
The Lancet. Oncology|August 23, 2015
Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 studyJean-Pierre J Issa, Gail Roboz, David Rizzieri, et al.
Scientific Reports|September 19, 2013
Epigenetic silencing of microRNA-203 is required for EMT and cancer stem cell propertiesJoseph H Taube, Gabriel G Malouf, Emily Lu, et al.
Cancer Research|November 6, 2009
Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinomaYasuhiro Goto, Keiko Shinjo, Yutaka Kondo, et al.
Clinical Epigenetics|May 14, 2020
Promoter methylation changes in ALOX12 and AIRE1: novel epigenetic markers for atherosclerosisJee Yeon Kim, Bong-Geun Choi, Jaroslav Jelinek, et al.
The Lancet. Haematology|May 8, 2019
Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trialGuillermo Garcia-Manero, Gail Roboz, Katherine Walsh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2002
Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylateHagop M Kantarjian, Susan O'Brien, Jorge E Cortes, et al.
Plos One|November 1, 2023
Postmortem toxicology findings from the Camden Opioid Research InitiativeDara M Kusic, Jessica Heil, Stefan Zajic, et al.
Cancer|December 7, 2017
Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemiaGail J Roboz, Hagop M Kantarjian, Karen W L Yee, et al.
Cancer Research|January 1, 2016
Targeting Calcium Signaling Induces Epigenetic Reactivation of Tumor Suppressor Genes in CancerNoël J-M Raynal, Justin T Lee, Youjun Wang, et al.
Pageof 21